Risk Assessment of Fetal Growth Abnormalities From Placental Dysfunction

Abstract

Fetal growth abnormalities, including fetal growth restriction (FGR) and macrosomia, pose significant clinical challenges and are commonly linked to placental dysfunction. This review provides a comprehensive assessment of risk factors, underlying mechanisms, clinical features, diagnostic approaches, management strategies, and recent advances in addressing fetal growth abnormalities associated with placental pathology. Emphasis is placed on evidence-based guidelines, current research findings, and the practical implications for optimizing perinatal outcomes.

Introduction

Fetal growth abnormalities, particularly those resulting from placental dysfunction, are major contributors to perinatal morbidity and mortality worldwide. The placenta plays a pivotal role in fetal development by mediating nutrient and oxygen transfer, waste elimination, and endocrine signaling. Disruption of these functions can result in either fetal growth restriction or, less commonly, excessive fetal growth. Given the complexity and multifactorial nature of these conditions, risk assessment and management require a multidisciplinary, evidence-based approach.

Epidemiology / Disease Burden

Globally, FGR affects approximately 5-10% of pregnancies, with higher prevalence in low- and middle-income countries. Placental dysfunction is implicated in up to 60% of FGR cases. Macrosomia, defined as birth weight above the 90th percentile for gestational age, is also increasingly recognized, particularly in the context of maternal metabolic disorders. Both conditions are associated with increased risks of stillbirth, neonatal morbidity, and long-term adverse health outcomes including metabolic syndrome and cardiovascular disease.

Pathophysiology

The pathogenesis of fetal growth abnormalities from placental dysfunction is multifaceted. Impaired trophoblast invasion and abnormal remodeling of maternal spiral arteries lead to inadequate uteroplacental perfusion, resulting in chronic fetal hypoxia and nutrient deprivation. This can manifest as FGR, particularly when placental insufficiency arises early in gestation. In contrast, increased placental nutrient transport in the setting of maternal hyperglycemia can promote excessive fetal growth. Placental histopathological findings may include infarcts, villous immaturity, and increased syncytial knots, which correlate with clinical severity.

Risk Factors

Risk factors for placental dysfunction and subsequent fetal growth abnormalities are diverse. Maternal factors include chronic hypertension, preeclampsia, diabetes mellitus, autoimmune disorders, thrombophilias, and advanced maternal age. Lifestyle factors such as smoking, substance abuse, and inadequate prenatal care also contribute. Fetal factors include chromosomal abnormalities and congenital infections. A history of prior FGR or stillbirth further increases risk, underscoring the importance of thorough obstetric history taking.

Clinical Features

Fetal growth abnormalities may present with reduced symphyseal-fundal height, decreased fetal movements, or abnormal findings on routine ultrasound. In cases of FGR, Doppler studies often reveal abnormal umbilical artery or uterine artery waveforms, reflecting compromised placental blood flow. Macrosomia may be suspected in pregnancies complicated by maternal diabetes or excessive gestational weight gain, with increased abdominal circumference on ultrasound.

Diagnosis

The diagnosis of fetal growth abnormalities relies on serial ultrasound assessments of fetal biometry, including estimated fetal weight and growth percentiles. Doppler velocimetry of the umbilical artery, middle cerebral artery, and ductus venosus aids in assessing placental function and fetal well-being. Maternal serum biomarkers such as placental growth factor (PlGF) and pregnancy-associated plasma protein A (PAPP-A) are under investigation for early prediction of placental dysfunction. Additional evaluation for underlying etiologies, such as maternal thrombophilia screening or infectious workup, may be warranted based on clinical context.

Treatment & Management

Management strategies are tailored to gestational age, severity of fetal compromise, and underlying maternal or fetal conditions. Close surveillance with serial ultrasound, Doppler studies, and non-stress testing is essential. In cases of severe FGR with evidence of fetal compromise, early delivery may be indicated, balancing the risks of prematurity against intrauterine demise. Maternal optimization, including blood pressure control, glycemic management, and thromboprophylaxis when indicated, is crucial. Multidisciplinary care involving obstetricians, neonatologists, and maternal-fetal medicine specialists improves outcomes.

Recent Advances / Emerging Therapies

Recent research has focused on the identification of novel biomarkers for early detection of placental dysfunction, including cell-free fetal DNA and microRNAs. Advances in ultrasound technologies, such as three-dimensional power Doppler and elastography, offer enhanced assessment of placental structure and function. Experimental therapies, including maternal administration of sildenafil citrate, antioxidants, and statins, are under investigation for their potential to improve uteroplacental blood flow and fetal growth, though robust clinical data are pending.

Guideline Recommendations

Major societies, including the American College of Obstetricians and Gynecologists (ACOG) and the International Society for Ultrasound in Obstetrics and Gynecology (ISUOG), recommend risk stratification based on maternal history, routine ultrasound screening, and Doppler studies for at-risk pregnancies. Delivery planning should consider gestational age, fetal condition, and the availability of neonatal intensive care. Aspirin prophylaxis is recommended for women at high risk of preeclampsia, which may reduce the incidence of FGR.

Conclusion

Fetal growth abnormalities secondary to placental dysfunction require meticulous risk assessment, timely diagnosis, and individualized management to optimize maternal and neonatal outcomes. Ongoing advances in diagnostic modalities and emerging therapeutic strategies hold promise for improving early detection and intervention. Adherence to guideline-based care, multidisciplinary collaboration, and continued research are essential for addressing the significant burden of these conditions in clinical practice.